BRPI0812170A2 - Moduladores de gama secretase - Google Patents

Moduladores de gama secretase

Info

Publication number
BRPI0812170A2
BRPI0812170A2 BRPI0812170-2A2A BRPI0812170A BRPI0812170A2 BR PI0812170 A2 BRPI0812170 A2 BR PI0812170A2 BR PI0812170 A BRPI0812170 A BR PI0812170A BR PI0812170 A2 BRPI0812170 A2 BR PI0812170A2
Authority
BR
Brazil
Prior art keywords
secretase
range modulators
modulators
range
secretase range
Prior art date
Application number
BRPI0812170-2A2A
Other languages
English (en)
Inventor
Zhaoning Zhu
William J Greenlee
Xianhai Huang
Brian A Mckittrick
John W Clader
Mark D Mcbriar
Anandan Palani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0812170A2 publication Critical patent/BRPI0812170A2/pt
Publication of BRPI0812170A8 publication Critical patent/BRPI0812170A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0812170A 2007-06-01 2008-05-28 Moduladores de gama secretase BRPI0812170A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94140507P 2007-06-01 2007-06-01
US98448407P 2007-11-01 2007-11-01
PCT/US2008/006734 WO2008153793A2 (en) 2007-06-01 2008-05-28 Gamma secretase modulators

Publications (2)

Publication Number Publication Date
BRPI0812170A2 true BRPI0812170A2 (pt) 2014-12-02
BRPI0812170A8 BRPI0812170A8 (pt) 2016-02-10

Family

ID=40084164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812170A BRPI0812170A8 (pt) 2007-06-01 2008-05-28 Moduladores de gama secretase

Country Status (18)

Country Link
US (1) US8426403B2 (pt)
EP (1) EP2152695A2 (pt)
JP (1) JP5495331B2 (pt)
KR (1) KR20100037053A (pt)
CN (1) CN101809016A (pt)
AR (1) AR066152A1 (pt)
AU (1) AU2008263207B2 (pt)
BR (1) BRPI0812170A8 (pt)
CA (1) CA2689948A1 (pt)
CL (1) CL2008001560A1 (pt)
CO (1) CO6241123A2 (pt)
EC (1) ECSP099776A (pt)
IL (1) IL202315A0 (pt)
MX (1) MX2009013131A (pt)
PE (1) PE20090363A1 (pt)
RU (1) RU2009148866A (pt)
TW (1) TW200914459A (pt)
WO (1) WO2008153793A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
WO2010054067A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009314205A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Gamma secretase modulators
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
EP2379566A2 (en) * 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
US20120245158A1 (en) * 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
WO2010147969A2 (en) * 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (en) * 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2015084752A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
CN111741948B (zh) * 2018-02-28 2023-11-10 日本烟草产业株式会社 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1065324A (en) 1974-05-13 1979-10-30 E.R. Squibb And Sons 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles
CH594667A5 (en) 1974-05-31 1978-01-13 Squibb & Sons Inc Hexahydro-2H-pyrazolo(4,3-C) pyridine derivs
US3979381A (en) 1975-08-11 1976-09-07 E. R. Squibb & Sons, Inc. Thiopyrano[4,3-c] pyrazoles
US4003890A (en) 1976-05-27 1977-01-18 E. R. Squibb & Sons, Inc. Benzylidene pyrano[4,3-c]pyrazoles
US4065617A (en) 1977-02-04 1977-12-27 E. R. Squibb & Sons, Inc. 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines
US6054590A (en) * 1998-03-25 2000-04-25 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
JP2003528073A (ja) * 2000-03-20 2003-09-24 エヌ・ジーン リサーチ ラボラトリーズ インコーポレイテッド プロペンカルボン酸アミドキシム誘導体、その製法、及びこの誘導体を含有する医薬組成物
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005065069A2 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2006001877A2 (en) 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1750719A2 (en) 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
EP2261218B1 (en) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI386207B (zh) * 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
GEP20115139B (en) * 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
AU2008263206A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ

Also Published As

Publication number Publication date
CA2689948A1 (en) 2008-12-18
JP5495331B2 (ja) 2014-05-21
AU2008263207A1 (en) 2008-12-18
KR20100037053A (ko) 2010-04-08
US8426403B2 (en) 2013-04-23
AR066152A1 (es) 2009-07-29
CN101809016A (zh) 2010-08-18
RU2009148866A (ru) 2011-07-20
ECSP099776A (es) 2010-01-29
BRPI0812170A8 (pt) 2016-02-10
WO2008153793A3 (en) 2009-03-19
US20100256128A1 (en) 2010-10-07
CL2008001560A1 (es) 2009-05-22
MX2009013131A (es) 2010-01-15
TW200914459A (en) 2009-04-01
CO6241123A2 (es) 2011-01-20
EP2152695A2 (en) 2010-02-17
WO2008153793A2 (en) 2008-12-18
IL202315A0 (en) 2010-06-30
AU2008263207A2 (en) 2010-01-28
AU2008263207B2 (en) 2013-10-03
PE20090363A1 (es) 2009-04-01
JP2010529015A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
BRPI0814256A2 (pt) Inibidores de tetrahidropiranocromeno gama secretase
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
BRPI0921348A2 (pt) moduladores heterocíclicos da gama secretase
BRPI0917394A2 (pt) moduladores de mif
BRPI0815135A2 (pt) Derivados de azepina como inibidores de gama secretase.
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0921327A2 (pt) Combinação de herbicida-protetor
IL206172A0 (en) Gamma secretase modulators
IL201960A0 (en) Gamma secretase modulators
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0813230A2 (pt) Moduladores de calicreína 7
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0915991A2 (pt) derivados de sulfamida substituída
BRPI0821162A2 (pt) Dispositivo de maçaneta
BRPI0822919A2 (pt) Dispositivo de travamento de diferencial
IL202315A0 (en) Gamma secretase modulators
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
BRPI0914596A2 (pt) combinação de guindaste

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.